Related references
Note: Only part of the references are listed.Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients
Hideo Shigematsu et al.
SUPPORTIVE CARE IN CANCER (2020)
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients
Yuqin Ding et al.
PLOS ONE (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Bulent Cetin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy of two-weekly nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for breast cancer
Fei Xie et al.
NANOMEDICINE (2019)
Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial
Kathryn J. Ruddy et al.
BREAST (2019)
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial A Randomized Phase 3 Clinical Trial
Luca Gianni et al.
JAMA ONCOLOGY (2018)
Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group
Shigeru Tsuyuki et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2016)
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer-results at the time of surgery
M. Untch et al.
ANNALS OF ONCOLOGY (2011)
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study
Nicholas Robert et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast Cancer
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02
Kojiro Shimozuma et al.
SUPPORTIVE CARE IN CANCER (2009)
Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer
WJ Gradishar et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Measuring the side effects of taxane therapy in oncology - The functional assessment of cancer therapy-taxane (FACT-taxane)
D Cella et al.
CANCER (2003)
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741
ML Citron et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
